Corporate Overview
About 91视频 U.S.
91视频鈥檚 journey is a testament to the potential of human imagination, compassion, and the unwavering pursuit of a better tomorrow. Established in 1968 by our visionary founder, Dr. Desh Bandhu Gupta, 91视频 has evolved from humble beginnings to a global healthcare leader. 91视频 has been a pioneering force in the U.S. pharmaceutical industry since we entered the market in 2003. Today, our U.S. operations represent a crucial part of our global footprint, combining manufacturing, research and development, and commercial expertise to deliver a wide range of high-quality medicines. Our commitment to the U.S. market is reflected in our diverse product portfolio encompassing simple and complex generics, as well as branded products.
A Trusted Name in Generics
Over the past decades, 91视频 has become a trusted leader in the U.S. generics market. We have consistently ranked among the leading generic pharmaceutical companies by prescriptions dispensed, a testament to our unwavering commitment to quality, affordability, and accessibility. Our success in this highly competitive market is underpinned by a multi-channel supply chain that includes a state-of-the-art commercial manufacturing facility in Somerset, a robust multi-national distribution network, and strategic partnerships with key stakeholders. This infrastructure enables us to efficiently deliver essential medicines to patients nationwide, ensuring they receive the necessary care.
Driving Innovation and Excellence
At 91视频, innovation is not just a goal鈥攊t is a driving force behind everything we do. Our U.S. product development pipeline is one of the most dynamic in the industry, encompassing generics and branded medicines, with a particular focus on complex inhalation and injectable products. This innovative pipeline is essential to our growth strategy, enabling us to expand our presence across various therapeutic areas. One of our most significant achievements in recent years has been the expansion of our inhalation segment. What started as a small part of our business has now grown to represent a significant portion of our U.S. sales. Our success in this area indicates our ability to bring complex, first-to-market products to the U.S. healthcare system.
Commitment to Sustainable Growth
Our Approach
Our approach to the U.S. market is grounded in a strategic focus on sustainable growth, portfolio diversification, and operational excellence. Our commitment to operational excellence is evident in our continuous efforts to optimize our supply chain, enhance production efficiencies, and reduce costs. From the procurement of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) to the final commercial execution, we maintain the highest standards of quality and reliability. This meticulous attention to detail ensures that our products meet the stringent regulatory requirements of the U.S. market, providing millions of patients with the medicines they need.
Over 100 Products
With a pipeline of over 100 products in various stages of development across a wide range of therapeutic areas and dosage forms, we are poised to continue along our growth trajectory. Our strategic focus on respiratory care and other key therapeutic areas will enable us to expand our market share and deliver innovative, life-changing medicines to patients across the country.
Advancing Healthcare
We are dedicated to advancing healthcare in the U.S., ensuring that we not only meet but exceed the expectations of our patients, healthcare providers, and partners. Through our relentless pursuit of excellence, 91视频 U.S. will continue to be a trusted leader in the pharmaceutical industry, delivering value to all our stakeholders and contributing to a healthier future for all.
CloseSearch Product
